ImmunoGen Valuation

ImmunoGen Investor Information

About 91.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.28. ImmunoGen had not issued any dividends in recent years. Based on the analysis of ImmunoGen's profitability, liquidity, and operating efficiency, ImmunoGen is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.

ImmunoGen Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. ImmunoGen has an asset utilization ratio of 82.43 percent. This suggests that the Company is making $0.82 for each dollar of assets. An increasing asset utilization means that ImmunoGen is more efficient with each dollar of assets it utilizes for everyday operations.

ImmunoGen Ownership Allocation

ImmunoGen has a total of 279.35 Million outstanding shares. The majority of ImmunoGen outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in ImmunoGen to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in ImmunoGen. Please pay attention to any change in the institutional holdings of ImmunoGen as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.

ImmunoGen Profitability Analysis

The company reported the previous year's revenue of 287.61 M. Net Loss for the year was (73.52 M) with loss before overhead, payroll, taxes, and interest of (104.76 M).

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.